Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
Posted:
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
Operating System Leverage in Electronic Records, or O.S.L.E.R., is a fully digital AI staff member, an AI agent that can see the screen and use the mouse and keyboard just like you do.
If you want to find out more about…
Discovery Park have secured a number of industry leading suppliers and experts who will be on-site to introduce you to the latest technologies and solutions for your business needs.
There will also be freebies and goodies up for grabs!
Tuesday…